Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the recipient of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 11,790,000 shares, a decline of 5.1% from the October 15th total of 12,420,000 shares. Based on an average daily volume of 1,120,000 shares, the short-interest ratio is presently 10.5 days.

Citius Pharmaceuticals Trading Up 12.1 %

Shares of CTXR stock opened at $0.22 on Tuesday. The company has a market capitalization of $40.52 million, a P/E ratio of -0.93 and a beta of 1.66. Citius Pharmaceuticals has a 12-month low of $0.19 and a 12-month high of $1.07. The business’s 50 day moving average is $0.43 and its two-hundred day moving average is $0.60.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC acquired a new position in Citius Pharmaceuticals during the second quarter worth $5,928,000. BNP Paribas Financial Markets increased its stake in shares of Citius Pharmaceuticals by 88.5% during the first quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock worth $62,000 after purchasing an additional 32,686 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Citius Pharmaceuticals by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after purchasing an additional 104,889 shares during the last quarter. Arkadios Wealth Advisors raised its position in shares of Citius Pharmaceuticals by 50.0% during the 2nd quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock worth $88,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Citius Pharmaceuticals in the 2nd quarter valued at about $69,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.